These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27808597)

  • 1. Rethinking the INN system for therapeutic antibodies.
    Pottier J; Chastang R; Dumet C; Watier H
    MAbs; 2017 Jan; 9(1):5-11. PubMed ID: 27808597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The INNs and outs of antibody nonproprietary names.
    Jones TD; Carter PJ; Plückthun A; Vásquez M; Holgate RG; Hötzel I; Popplewell AG; Parren PW; Enzelberger M; Rademaker HJ; Clark MR; Lowe DC; Dahiyat BI; Smith V; Lambert JM; Wu H; Reilly M; Haurum JS; Dübel S; Huston JS; Schirrmann T; Janssen RA; Steegmaier M; Gross JA; Bradbury AR; Burton DR; Dimitrov DS; Chester KA; Glennie MJ; Davies J; Walker A; Martin S; McCafferty J; Baker MP
    MAbs; 2016; 8(1):1-9. PubMed ID: 26716992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International nonproprietary names for monoclonal antibodies: an evolving nomenclature system.
    Guimaraes Koch SS; Thorpe R; Kawasaki N; Lefranc MP; Malan S; Martin ACR; Mignot G; Plückthun A; Rizzi M; Shubat S; Weisser K; Balocco R
    MAbs; 2022; 14(1):2075078. PubMed ID: 35584276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Think INN, prescribe INN, dispense INN: good professional practice.
    Prescrire Int; 2000 Dec; 9(50):184-90. PubMed ID: 11475502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common stems: international nonproprietary names (INNs): common INN stems provide key information.
    Prescrire Int; 2007 Oct; 16(91):192. PubMed ID: 17926829
    [No Abstract]   [Full Text] [Related]  

  • 6. International Nonproprietary Names (INN) for pharmaceutical substances.
    Kopp-Kubel S
    Bull World Health Organ; 1995; 73(3):275-9. PubMed ID: 7614659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of the database on nonproprietary names of drugs].
    Hashiba S; Takenaka Y; Nakadate M
    Eisei Shikenjo Hokoku; 1989; (107):141-5. PubMed ID: 2636918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.
    Wilkinson I; Hale G
    MAbs; 2022; 14(1):2123299. PubMed ID: 36109838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Common international names and trademarks in the pharmaceutical field].
    Pasotti V
    Boll Chim Farm; 1989 Apr; 128(4):121-4. PubMed ID: 2775524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obstacles to the universal application of INNs.
    Prescrire Int; 2014 Oct; 23(153):248-51. PubMed ID: 25964979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Nonproprietary Names (INN). A World Health Organization activity.
    Jerome JB; Luback PM
    J Am Med Womens Assoc (1972); 1972 Oct; 27(10):536-8. PubMed ID: 4342347
    [No Abstract]   [Full Text] [Related]  

  • 12. The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough.
    Loizides U; Dominici M; Manderson T; Rizzi M; Robertson JS; de Sousa Guimarães Koch S; Timón M; Balocco R
    Cytotherapy; 2021 May; 23(5):357-366. PubMed ID: 33820700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INN: International Nonproprietary Name. Common stems--gest-.
    Prescrire Int; 2010 Apr; 19(106):67. PubMed ID: 20568488
    [No Abstract]   [Full Text] [Related]  

  • 14. Proposed international nonproprietary names (Prop. INN): List 55.
    WHO Chron; 1986; 40(1 Suppl):1-20. PubMed ID: 3739337
    [No Abstract]   [Full Text] [Related]  

  • 15. How INNs are created. Making drug names safer by contributing to INN selection.
    Prescrire Int; 2015 Jun; 24(161):162-5. PubMed ID: 26436175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naming drug substances at the national level: mainly in the United Kingdom and the United States.
    Prescrire Int; 2012 Nov; 21(132):279. PubMed ID: 23210269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Operational rules for the implementation of INN prescribing.
    Van Bever E; Wirtz VJ; Azermai M; De Loof G; Christiaens T; Nicolas L; Van Bortel L; Vander Stichele R
    Int J Med Inform; 2014 Jan; 83(1):47-56. PubMed ID: 24168761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.